TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy infant 46 to 74 days of age (both inclusive)~* Born at full term of pregnancy (≥37 weeks) and/or with a birth weight≥2.5 kg~* Subject's parent(s) or legal representative able to comply with the study procedures~Exclusion Criteria:~* Participation in another clinical study investigating a vaccine, drug, medical device, or medical procedure~* Receipt of any vaccine in the 4 weeks preceding each study vaccination~* Previous vaccination against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, Haemophilus influenzae type b, meningococcal, pneumococcal, rotavirus infection~* Know or suspected congenital, hereditary or acquired immunodeficiency~* History of seizures or encephalopathy~* Known thrombocytopenia~* Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular injection~* Chronic illness that could interfere with trial conduct or completion~* Known or suspected hypersensitivity to any of the study vaccines' active substance or excipients or history of a life-threatening reaction to a vaccine(s) containing the same substances as the study vaccines~* Contraindication to any of the study vaccines~* Known personal or maternal history of hepatitis B or hepatitis C seropositivity~* History of diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, Haemophilus influenzae type b or meningococcal serogroup C infection~* Receipt of immune globulin, blood or blood-derived products, immunosuppressive drugs, systemic corticosteroid since birth~* Identified as a natural or adopted child of the investigator or employee with direct involvement in the current study.

- Gender: ALL
- Minimum Age: 46 Days
- Maximum Age: 76 Days
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: EXPERIMENTAL): None
- Group 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Postoperative Analgesia Following Wisdom Teeth Removal: Ropivacaine Versus Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patient must have given his/her informed and signed consent~* The patient must be insured or beneficiary of a health insurance plan~* The patient is available for 3 months of follow-up~* American Society of Anesthesiology (ASA) score of 1, 2 or 3~* Patient programmed for surgical removal of all 4 wisdom teeth, excluding all other teeth, under general anesthesia~Exclusion Criteria:~* The patient is participating in another study~* The patient is in an exclusion period determined by a previous study~* The patient is over 18 years old and under judicial protection, under tutorship or curatorship~* The patient (or legal representative)refuses to sign the consent~* It is impossible to correctly inform the patient~* The patient is pregnant, parturient, or breastfeeding~* Ineffective contraceptive~* Addiction or chronic pain treated with morphine~* Contra-indication for regional anesthesia (eg congenital or acquired coagulopathy, infection, allergy)~* Contra-indication to local anesthetics, general anesthetics and analgesics used in the protocol.~* Difficult cooperation, psychiatric disorders that could interfere with assessments~* Hypersensitivity to ropivacaine or other local anesthetics with amide links~* Contra-indication for the use of NaCl 0.9%: all states of sodium and water retention (especially heart failure, edema and ascites syndrome associated with cirrhosis)

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Patients in this arm will have standard anesthesia with the injection of placebo solution into the vestibular of each tooth to be extracted
- Ropivacaine (Type: EXPERIMENTAL): Patients in this arm will have general anesthesia with injection of ropivacaine into the vestibular next to each tooth to be extracted.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity of a JE-CV as a Booster Dose After a Primary Vaccination With SA14-14-2 Vaccine

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1 Children aged 1 to \<5 years on the day of inclusion~2. History of received 1 dose of SA14-14-2 vaccine 12-24 months prior to enrollment~3. In good general health at the time of inclusion~4. Provision of informed consent by the parent(s) or legal guardian(s)~Exclusion Criteria:~1. Receipt of blood or blood products in the past 3 months.~2. Acute febrile illness on the day of vaccination.( BT \> 38 C)

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 5 Years
- Healthy Volunteers: t

Study Arms:
- a live attenuated chimeric JE vaccine (Type: EXPERIMENTAL): Children were received JE-CV as a booster dose after vaccinated with SA14-14-2 vaccine as a first dose regimen 12-24 months before.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Silymarin on the Prevention of Hepatotoxicity From Antituberculosis Drugs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* tuberculosis cases~* treated with isoniazid, rifampicin, ethambutol and pyrazinamide~Exclusion Criteria:~* no known liver disease (HBV, HCV), and HIV infection~* normal ALT level before enrollment~* refuse to participate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- silymarin (Type: ACTIVE_COMPARATOR): Silymarin 140 mg three times a day for 4 weeks
- placebo (Type: PLACEBO_COMPARATOR): Placeo~1 tab three times a day for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age older than 50 years~* Fulfilled the Chuang criteria~* And currently:~  * PMR-AS\> 10~ * Absence of signs or symptoms of other musculoskeletal or connective tissue conditions~* Able to give informed consent~* Concomitant treatments with methotrexate or hydroxy-chloroquine are permitted if stable dose since 3 months.~Exclusion Criteria:~* Clinical symptoms of giant cell arteritis~* Uncontrolled dyslipidemia, high blood pressure or cardiovascular disease~* History of major organ or haematopoietic stem cell/marrow transplant~* Clinical evidence of significant unstable or uncontrolled acute or chronic diseases not due to PMR~* Planned surgical procedure within 12 months after randomization.~* History of malignant neoplasm within the last 5 years.~* Current active infection~* Patient with elevated ALT or AST\> 5 ULN

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tocilizumab (Type: EXPERIMENTAL): 6 Intravenous infusions of tocilizumab in a dosage of 8 mg/kg (or 4 mg/kg depending on biological results as mentioned by the SPC of Tocilizumab for the rheumatoid arthritis) every 4 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): 6 Intravenous infusions of placebo (sterile sodium chloride solution) every 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of the Combination of Loop With Thiazide-type Diuretics in Patients With Decompensated Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of chronic heart failure~* Admission for acute decompensated heart failure~* There is no prespecified inclusion criterion with respect to heart failure etiology and/or ejection fraction~* Receipt of an oral loop diuretic for at least 1 month before hospitalization, at a dose between 80 mg and 240 mg daily in the case of furosemide and an equivalent dose in the case of a different loop diuretic (20 mg of torasemide or 1 mg of bumetanide was considered to be equivalent to 40 mg of furosemide)~Exclusion Criteria:~* Other etiologies of fluid overload different from heart failure~* Hyponatremia: any symptomatic sodium value or a sodium level below 125mmol/l~* Unstable patients: acute coronary syndrome, cardiogenic shock or ICU admission.~* Patients requiring inotropic agents or renal replacement therapies~* Life expectancy \< 6 months~* Prior treatment with thiazide-type diuretics~* Aldosterone antagonists are permitted if the patient had been taking them on a long-term basis (at least 30 days before randomisation)~* Pregnancy or breastfeeding period~* Active alcoholism and/or other substance abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Loop plus thiazide-type diuretic (Type: ACTIVE_COMPARATOR): Loop diuretic plus hydrochlorothiazide
- Loop diuretic plus placebo (Type: PLACEBO_COMPARATOR): Loop diuretic plus placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Huashi Baidu Granule in the Treatment of Pediatric Patients With Mild Coronavirus Disease 2019

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* attend the COVID-19 Fangcang Shelter Hospitals in Shanghai, China~* with laboratory-confirmed COVID-19~* compliance with the diagnostic criteria for mild COVID-19~* age 3 to 18 years.~Exclusion Criteria:~* with underlying disease(s) such as chronic pulmonary disease, immunodeficiency, tumors, etc.,~* allergy or intolerance to taking Chinese medicine herbs or compound pholcodine oral solution~* with poor compliance (defined as inability to comply with the protocol)~* decline to participate

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- intervention group (Type: EXPERIMENTAL): receive oral HSBDG for 5 consecutive days
- control group (Type: OTHER): receive compound pholcodine oral solution for 5 consecutive days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant females (18-26 weeks of gestation)~* documented HIV-1 infection~* Receiving darunavir/ritonavir, darunavir/cobicistat, etravirine, or rilpivirine at the time of study entry~* Willing to remain on darunavir/ritonavir, darunavir/cobicistat, etravirine, or rilpivirine as well as a background regimen, for the duration of the study, including 12 weeks postpartum~* Able to comply with the protocol requirements and to provide written informed consent.~Exclusion Criteria:~* Patients with any currently active acquired immune deficiency syndrome (AIDS) defining illness and AIDS-related opportunistic infection~* Patients using cytokine inhibitors (e.g., thalidomide), anabolic hormones, cytokines (e.g., IL-2, INF), efavirenz, hydroxyurea, oral hypoglycemics, systemic chemotherapy or known teratogenic agent~* Use of an investigational agent within 90 days~* Any known fetal anomaly~* Any current obstetric complication, including multiple gestations and pre-term labor~* Hepatitis B and/or C virus infection~* Grade 2 or higher anemia~* Thyroid disease~* Uncontrolled Diabetes Mellitus Types I and II, or gestational diabetes, as determined by the investigator

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1: Darunavir 600 /Ritonavir 100 (Type: EXPERIMENTAL): TMC114 (darunavir) Two 300 milligram (mg) or one 600 mg tablet twice daily up to 12 weeks postpartum / ritonavir one 100 mg tablet twice daily with darunavir up to 12 weeks postpartum.
- Group 2: Darunavir 800/Ritonavir 100 (Type: EXPERIMENTAL): TMC114 (darunavir) 800mg tablet once daily up to 12 weeks postpartum/ ritonavir one 100 mg tablet once daily with darunavir up to 12 weeks postpartum.
- Group 3: Etravirine (Type: EXPERIMENTAL): TMC125 (etravirine) 200 mg (1\*200 mg/2\*100 mg) tablets twice daily up to 12 weeks postpartum.
- Group 4: Rilpivirine (Type: EXPERIMENTAL): TMC278 (rilpivirine) One 25 mg tablet once daily up to 12 weeks postpartum.
- Group 5: Darunavir 800/Cobicistat 150 (Type: EXPERIMENTAL): Fixed dose combination (FDC) tablet of TMC114 (darunavir) 800 mg and cobicistat 150 mg once daily up to 12 weeks postpartum.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Atropine-effect During Propofol/Remifentanil Induction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients requiring general anaesthesia;~* Patient's age ≥ 18 years and older;~* Patient and surgical procedure appropriate for treatment with either sufentanil or remifentanil.~Exclusion Criteria:~* Patient's refusal;~* Pregnancy;~* Patient's age \< 18 years;~* Patients in which atropine is contra-indicated, such as severe aortic valve stenosis, hypertrophic cardiomyopathy or coronary artery disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- General anesthesia + placebo (Type: PLACEBO_COMPARATOR): Propofol/remifentanil anesthesia + saline
- General anesthesia + atropine (Type: ACTIVE_COMPARATOR): Propofol/remifentanil anesthesia + atropine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: S. Aureus Screening and Decolonization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patient who are 18 years and older, able to give informed consent and willing to complete the study decolonization protocol.~* Surgery must be scheduled 2 weeks in the future to allow completion of the study protocol prior to the scheduled operation.~* Patients will be admitted from home the day of the surgery or have the surgery done on an outpatient basis.~Exclusion Criteria:~* Currently on antibiotic therapy, allergy to mupirocin or CHG.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- standard of care (Type: ACTIVE_COMPARATOR): Surgeon's routine for preoperative showering.
- antiseptic bundle (Type: EXPERIMENTAL): Patients to use study bundle for 5 days prior to scheduled surgery with the following medications to use at home.~1. Chlorhexidine gluconate soap applied for bathing daily.~2. Chlorhexidine gluconate mouthrinse used to rinse mouth twice daily.~3. Nasal mupirocin to applied inside nostrils twice daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multiple-dose Tolerability and Pharmacokinetic Studies of Benapenem inClinical Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female healthy subjects, aged 18\~45;~* Body weight ≥ 50 kg and body mass index 19.0\~24.0 kg/m2;~* To the test, physical examination, blood routine, urine routine, liver and kidney functions, and related examinations normal, or mild abnormalities in indicators while without clinical significance as indicated by the investigator;~* Normal or mild abnormalities without clinical significance in the standard 12-lead ECG;~* Signing informed consent form.~Exclusion Criteria:~* Regular smoking, alcohol abuse, and drug abuse;~* Use of drugs with known damage to an organ within three months;~* History of specific allergies , or history of drug allergy, especially those allergic to lactams and excipients of test drug;~* Febrile illnesses within three days before the screening;~* Patients with mental illness or psychotic disorder in the past;~* Past nervous system diseases (epilepsy, stroke, cerebrovascular disorder, etc.), gastrointestinal disorder (such as stomach ulcers, gastritis, etc.) or disorder of other systems (such as cardiovascular, respiratory, hematological, or endocrine system, etc.) diseases or medical history.~* Habitually taking any medication, including traditional Chinese medicine;~* Having taken any medication that may affect test results within two weeks before the screening, such as antibiotics, NSAIDs, aluminum- or magnesium-containing antacids, diuretics, anticoagulants, central nervous system depressants, and any drug that may affect the drug absorption;~* Having participated in other investigational drug trial in the preceding three months;~* Blood donation for 360 ml or more within three months before the screening;~* Heart rate\<50bpm or \>100bpm; 12)Systolic blood pressure \<90 mmHg or ≥140 mmHg, diastolic blood pressure ≥90mmHg or \<60mmHg;~* Women who are pregnant or breastfeeding, or who may be pregnant without adopting acceptable contraception, or who have a positive result in serum pregnancy test;~* Women who are planning to become pregnant within 6 months, or male subjects who are planning to make his spouse pregnant within 6 months;~* HBsAg, HCV antibody, HIV antibody, and Treponema pallidum antibody positive;~* Urine drug-of-abuse testing positive;~* Any other factor that makes the subject not suitable for the trial as indicated by the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Banapenem C1 group (Type: EXPERIMENTAL): 250mg Once daily for 7
- Banapenem C2group (Type: EXPERIMENTAL): 500mg Once daily for 7
- Banapenem C3group (Type: EXPERIMENTAL): 1000mg Once daily for 7

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With MPS VI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Patient consent~* Patient must be seven years of age or older~* Patient must have documented biochemical or genetic proof of MPS VI~* The patient must be able to walk independently at least 5 meters and no more than 270 meters in the first 6 minutes, or no more then 400 meters total in 12 minutes, in the screening 12-minute walk test~* If female of childbearing potential, patient must have a negative pregnancy test~Exclusion Criteria~* Patient is under consideration for or has undergone a successful bone marrow transplant (BMT)~* Patient refuses or is unable to complete all screening evaluations~* Pregnant or lactating patient~* Patient has received an investigational drug within 30 days prior to study enrollment~* Patient has been previously treated with rhASB~* Patient has a medical condition, serious intercurrent illness, or other extenuating circumstance that may significantly confound study results or decrease study compliance~* The patient has clinically significant spinal cord compression~* The patient has known hypersensitivity to rhASB or to components of the active or placebo test solutions

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- rhASB (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Body mass index (BMI) in the range 22-45~* Blood glucose criteria must be met~* Not currently on drug therapy for type 2 diabetes~Exclusion Criteria:~* Type 1 diabetes~* Evidence of serious diabetic complications~* Evidence of serious cardiovascular conditions~* Laboratory value abnormalities as defined by the protocol~* Other protocol-defined exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete